Online Inquiry


As an innovative and rapidly evolving radiopharmaceutical, RDC (Radionuclide Drug Conjugate) is composed of four crucial components which include radionuclides, chelator, linker, and targeting molecule. Combined with targeting vector and bifunctional radioactive particles applied to conduct cytotoxicity and imaging, RDC can be used as anti-cancer drugs, clinical and pre-clinical imaging agents.

Consist of targeting vector and radioactive particles, RDC can be applied in tumor therapy with accuracy in tumor cell damage. A myriad of RDC is now utilized in the clinical treatment methods for solid cancer and hematologic cancer.

  • RDC Development for Solid Cancer
  • RDC Development for Hematologic Cancer

RDC is widely applied as diagnostic imaging agent which can provide both imaging results and additional information about the molecular characteristics of cancer.

RDC can be applied in cancer diagnosis and efficacy detection for clinical utilization, as well as applied in the cell and animal models monitoring imaging for pre-clinical utilization.

Our Service

Rdcthera, possessing top-notched equipment, can provide professional, high-quality, and cost-effective RDC development service and analysis service to promote your special RDC project. We are glad to share our experience and technology with you. Please contact us for more information.

For research use only. Not intended for any clinical use.

Rdcthera RDC

Rdcthera offers efficient, customized, and professional R&D services related to radionuclide drug conjugates.

Copyright © Rdcthera. All rights reserved. Privacy Policy | Cookie Policy